Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Sensory Nerve Regulation via H3K27 Demethylation Revealed in Akermanite Composite Microspheres Repairing Maxillofacial Bone Defect.

doi: 10.1002/advs.202400242

Figure Lengend Snippet: Figure 5. The Synergistic Effect of Trigeminal Sensory Nerve Cells on Osteogenesis. A) Heat map of different expressed genes between trigeminal nerve cells treated with complete F12 medium (CTRL) and D-P20Ak conditional medium. Fold change data was logarithmically processed. #, genes related to receptors in nerve cells. ##, gene encoding endothelin. ###, genes correlated with neuro-metabolism. *, genes regarding cytochrome P450 family and lipid metabolism. **, genes encoding central neurotransmitter. Three duplicates were tested for each group, P < 0.05. B) CGRP gene expression of mice trigeminal sensory nerve cells co-cultured with microsphere extraction medium for three days. CTRL, BMSCs cultured with only complete F12 medium. Three duplicates were tested for each group. *P < 0.05. C) ELISA showing the CGRP concentration in the supernatant of the trigeminal neurons, which were co-cultured with conditional medium for 3 days. CTRL, BMSCs cultured with only complete F12 medium. 3 duplicates were tested for each group,

Article Snippet: ELISA: The serum level of CGRP were evaluated using Mouse CGRP-I ELISA kit (EIAM-CGRP-1) from RayBiotech (Peachtree Corners, GA, USA) according to manufactory’s instructions.

Techniques: Gene Expression, Cell Culture, Extraction, Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Association of immune infiltration with psoriasis and AMI. ( A ) Relative abundance of distinct immune cell subsets in GSE161683 database. ( B ) Correlation between immune cell infiltration and the expression of SLPI, S100A9, IL1B, CYBB, CXCL8, S100A12, and CXCL1 in the Psoriasis cohort. ( C ) Relative abundance of distinct immune cell subsets in GSE66360 database. ( D ) Correlation between immune cell infiltration and the expression of SLPI, S100A9, IL1B, CYBB, CXCL8, S100A12, and CXCL1 in the AMI cohort.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Three-dimensional molecular docking diagrams of simvastatin with target proteins: ( A ) CXCL8, ( B ) IL1B, ( C ) S100A9, and ( D ) S100A12.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques:

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Expression of hub genes in serum of AMI patients and border zone of cardiac infarction in MI mice. ELISA was used to detect the expression of CXCL8 ( A ), IL-1B ( B ), S100A9 ( C ) and S100A12 ( D ) in serum of Normal and AMI patients. ( E ) The sham group and myocardial infarction 1 d, 3 d, 7 d heart tissue in mice of HE staining and CXCL8, IL-1B and S100A9 immunohistochemical staining and quantitative ( F – H ). ( I ) The mRNA expression of Il-8, Il-1b and S100a9 in cardiac tissue of MI mice on day 1, 3, 7 and sham group were detected.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: High expression of disease hub genes in psoriasis skin. ( A ) Immunohistochemical staining and quantitative ( B - E ) detection of the normal skin of patients with psoriasis skin disease in CXCL8, IL-1B, S100A9 and S100A12 expression.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Frontiers in Molecular Biosciences

Article Title: New Kid on the Block: The Efficacy of Phytomedicine Extracts Urox ® in Reducing Overactive Bladder Symptoms in Rats

doi: 10.3389/fmolb.2022.896624

Figure Lengend Snippet: The effects of UROX ® (840 mg p.o., once daily for 14 consecutive days) on retinyl acetate (RA)–induced changes in urothelium thickness and bladder blood flow.

Article Snippet: Based on ELISA experiments, the levels of the following biomarkers were determined in the bladder urothelium: Calcitonin Gene-Related Peptide (CGRP; Biomatik, CN EKU02858), Organic Cation Transporter 3 (OCT3; antibodies-online, CN ABIN6227163), Transient Receptor Potential Cation Channel, Subfamily V, Member 1 (TRPV1; LSBio, LS-F36019), E-Cadherin (CDH1; Abbexa Ltd., abx052816), Tight Junction Protein 1 (ZO1; Cusabio, CSB-E17287-r), ATP Citrate Lyase (ATP; LifeSpan BioSciences, LS-F10730), IL-1β (Cloud-Clone; SEA563Ra), IL6 (LifeSpan BioSciences; LS-F25921-1), TNF-α (LifeSpan BioSciences; LS-F5193), Malondialdehyde (Biomatik, CN EKF57996), 3-nitrotyrosine (LifeSpan BioSciences; CN LS-F40120-1).

Techniques:

Journal: Frontiers in Molecular Biosciences

Article Title: New Kid on the Block: The Efficacy of Phytomedicine Extracts Urox ® in Reducing Overactive Bladder Symptoms in Rats

doi: 10.3389/fmolb.2022.896624

Figure Lengend Snippet: The influence of the 14-day administration of Urox ® (840 mg p.o.) on biomarkers’ level (pg/ml) in the bladder urothelium: (A) TNF-α, (B) IL-1β, (C) IL-6, (D) CGRP, (E) ATP, (F) malondialdehyde, (G) 3-nitrotyrosine, (H) E-cadherin, (I) TRPV1, (J) OCT-3, and (K) Z01 in rats subjected to a single injection of retinyl acetate (RA). Values are expressed as mean ± SEM. ** p < 0.01, **** p < 0.001 versus saline, ^ p < 0.05, ^^^^ p < 0.0001 versus RA ( n = 15 rats per group). One-way ANOVA: for CGRP: F(3.56) = 115, p < 0.0001; for ATP: F(3.56) = 24, p < 0.0001; for malondialdehyde: F(3.56) = 51, p < 0.0001; for 3-nitrotyrosine: F(3.56) = 31, p < 0.0001; for E-cadherin: F(3.56) = 16, p < 0.0001; for TRPV1: F(3.56) = 113, p < 0.0001; for OCT-3: F(3.56) = 122, p < 0.0001; and for Z01: F(3.56) = 7.5, p < 0.0001. CON, control.

Article Snippet: Based on ELISA experiments, the levels of the following biomarkers were determined in the bladder urothelium: Calcitonin Gene-Related Peptide (CGRP; Biomatik, CN EKU02858), Organic Cation Transporter 3 (OCT3; antibodies-online, CN ABIN6227163), Transient Receptor Potential Cation Channel, Subfamily V, Member 1 (TRPV1; LSBio, LS-F36019), E-Cadherin (CDH1; Abbexa Ltd., abx052816), Tight Junction Protein 1 (ZO1; Cusabio, CSB-E17287-r), ATP Citrate Lyase (ATP; LifeSpan BioSciences, LS-F10730), IL-1β (Cloud-Clone; SEA563Ra), IL6 (LifeSpan BioSciences; LS-F25921-1), TNF-α (LifeSpan BioSciences; LS-F5193), Malondialdehyde (Biomatik, CN EKF57996), 3-nitrotyrosine (LifeSpan BioSciences; CN LS-F40120-1).

Techniques: Injection

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Differences in CGRP levels in plasma with and without PI. ( A ) Correlation of α-CGRP levels in PI-plasma and No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the 95% confidence interval (CI). ( B ) Difference in α-CGRP levels in PI-plasma (represented in green) vs. No PI-plasma (represented in black); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (PI-plasma median = 38.28 pg/mL, No PI-plasma median = 21.26 pg/mL, p ≤ 0.0001). ( C ) Correlation of β-CGRP levels in PI-plasma and No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in β-CGRP levels in PI-plasma (represented in light blue) vs. No PI-plasma (represented in pink); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (PI-plasma median = 6.909 pg/mL, No PI-plasma median = 6.200 pg/mL, p = ns (non-significant)). **** p < 0.0001.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics, Comparison

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Correlation of α-CGRP and β-CGRP in plasma samples. ( A ) Correlation of α-CGRP levels vs. β-CGRP plasma levels in No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Correlation of α-CGRP levels vs. β-CGRP levels in PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Comparison of α-CGRP levels in serum and plasma. ( A ) Correlation of α-CGRP serum vs. No PI-plasma levels. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Difference in α-CGRP levels in serum (represented in burgundy) vs. No PI-plasma (represented in black); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (serum median = 24.32 pg/mL, No PI-plasma median = 24.94 pg/mL, p = ns). ( C ) Correlation of α-CGRP serum levels vs. PI-plasma levels. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in α-CGRP levels in serum (represented in burgundy) vs. PI-plasma (represented in green); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (serum median = 13.63 pg/mL, PI-plasma median = 38.29 pg/mL, p ≤ 0.01). ** p < 0.010.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Comparison, Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Comparison of β-CGRP levels in serum and plasma. ( A ) Correlation of β-CGRP serum vs. No PI-plasma levels; the dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Difference in β-CGRP concentrations in serum (represented in burgundy) vs. plasma (represented in pink); data are shown as median with CI 95%. Comparisons were made using the Wilcoxon Signed-Rank test (serum median = 3.625 pg/mL, plasma median = 8.516 pg/mL, p ≤ 0.0001). ( C ) Correlation of β-CGRP serum vs. No PI-plasma levels when using PI; the dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in β-CGRP concentrations in serum (represented in burgundy) vs. No PI-plasma with PI (represented in blue); data are shown as median with CI 95%. Comparisons were made using the Wilcoxon Signed-Rank test (serum median = 1.716 pg/mL, plasma with PI median = 6.909 pg/mL, p ≤ 0.0001). **** p < 0.0001.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Comparison, Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Dynamics of CGRP levels along migraine treatment. ( A ) Changes in α-CGRP concentrations in No PI-plasma before starting the treatment (M0), 6 months after starting treatment (M6) ; Wilcoxon Signed-Rank test ( p < 0.01) and ( B ) after 12 months of the beginning of the treatment (M12); Friedman test followed by Dunn’s test. ( C ) Changes in β-CGRP levels in No PI-plasma at M0 and M6 after starting treatment; Wilcoxon Signed-Rank test (ns) and ( D ) M12 Friedman test followed by Dunn’s test. * p < 0.050, ** p < 0.010.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Analysis of CGRP levels in plasma depending on demographic variables. ( A ) Correlation of α-CGRP No PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Correlation of α-CGRP PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( C ) Correlation of β-CGRP No PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Correlation of β-CGRP PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( E ) Comparison of α-CGRP No PI-plasma levels from patients sorted by sex (column A median = 23.31 pg/mL; column B median = 26.09 pg/mL; p = ns). ( F ) Comparison of α-CGRP PI-plasma levels from patients sorted by sex. ( G ) Comparison of β-CGRP No PI-plasma levels by sex (column A median = 8.350 pg/mL; column B median = 8.849 pg/mL; p = ns). ( H ) Comparison of β-CGRP PI-plasma levels sorted by sex. Data are shown as median with CI 95%. The comparisons in ( E – H ) were made using Mann–Whitney U test.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics, Comparison, MANN-WHITNEY